GenSight Biologics Announces the Filing of its 2018 Universal Registration Document
20 Décembre 2019 - 6:00PM
Business Wire
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN:
FR0013183985, PEA-PME eligible), a biopharma company focused on
discovering and developing innovative gene therapies for retinal
neurodegenerative diseases and central nervous system disorders,
today announced the filing of its 2018 Universal Registration
Document in English with the French market authority (Autorité des
Marchés Financiers, or AMF) on December 20, 2019 under number
D.19-1035.
This Universal Registration Document may be consulted on the
Company’s website: www.gensight-biologics.com, under “Investors”,
and on the AMF’s website: www.amf-france.org. Printed copies of the
2018 Universal Registration Document are also available to the
public free of charge upon request at the Company’s headquarters
located 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.
About GenSight Biologics GenSight Biologics S.A. is a
clinical-stage biopharma company focused on discovering and
developing innovative gene therapies for retinal neurodegenerative
diseases and central nervous system disorders. GenSight Biologics’
pipeline leverages two core technology platforms, the Mitochondrial
Targeting Sequence (MTS) and optogenetics to help preserve or
restore vision in patients suffering from blinding retinal
diseases. GenSight Biologics’ lead product candidate, GS010, is in
Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a
rare mitochondrial disease that leads to irreversible blindness in
teens and young adults. Using its gene therapy-based approach,
GenSight Biologics’ product candidates are designed to be
administered in a single treatment to each eye by intravitreal
injection to offer patients a sustainable functional visual
recovery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191220005340/en/
GenSight Biologics Thomas Gidoin Chief Financial Officer
tgidoin@gensight-biologics.com +33 (0)1 76 21 72 20
RooneyPartners Media Relations Marion Janic
mjanic@rooneyco.com +1-212-223-4017
The Trout Group US Investor Relations Chad Rubin
crubin@troutgroup.com +1-646-378-2947
James Palmer Europe Investor Relations
j.palmer@orpheonfinance.com +33 7 60 92 77 74
GenSight Biologics (EU:SIGHT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
GenSight Biologics (EU:SIGHT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
